Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,090 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.
Hara N, Ichihara E, Kano H, Ando C, Morita A, Nishi T, Okawa S, Nakasuka T, Hirabae A, Abe M, Asada N, Ninomiya K, Makimoto G, Fujii M, Kubo T, Ohashi K, Hotta K, Tabata M, Maeda Y, Kiura K. Hara N, et al. Transl Lung Cancer Res. 2023 Oct 31;12(10):2098-2112. doi: 10.21037/tlcr-23-99. Epub 2023 Oct 26. Transl Lung Cancer Res. 2023. PMID: 38025818 Free PMC article.
Foreign body granuloma mimicking recurrence of malignant pleural mesothelioma.
Nakasuka T, Fujimoto N, Hara N, Miyamoto Y, Yamagishi T, Asano M, Nishi H, Kishimoto T. Nakasuka T, et al. Among authors: hara n. Respir Med Case Rep. 2015 Sep 7;16:95-6. doi: 10.1016/j.rmcr.2015.09.002. eCollection 2015. Respir Med Case Rep. 2015. PMID: 26744667 Free PMC article.
Patients' preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406.
Makimoto G, Hotta K, Oze I, Ninomiya K, Nakanishi M, Hara N, Kano H, Watanabe H, Hata Y, Nishii K, Nakasuka T, Itano J, Ninomiya T, Kubo T, Ohashi K, Ichihara E, Minami D, Sato A, Tabata M, Maeda Y, Kiura K. Makimoto G, et al. Among authors: hara n. Acta Oncol. 2020 Mar;59(3):324-328. doi: 10.1080/0284186X.2019.1679880. Epub 2019 Oct 25. Acta Oncol. 2020. PMID: 31650873 No abstract available.
Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.
Ichihara E, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Ochi N, Oda N, Hara N, Hotta K, Maeda Y, Kiura K. Ichihara E, et al. Among authors: hara n. Cancer Immunol Immunother. 2021 Jan;70(1):101-106. doi: 10.1007/s00262-020-02662-0. Epub 2020 Jul 10. Cancer Immunol Immunother. 2021. PMID: 32648165 Free PMC article.
Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis.
Senoo S, Miyahara N, Taniguchi A, Oda N, Itano J, Higo H, Hara N, Watanabe H, Kano H, Suwaki T, Fuchimoto Y, Kajimoto K, Ichikawa H, Kudo K, Shibayama T, Tanimoto Y, Kuyama S, Kanehiro A, Maeda Y, Kiura K; Okayama Respiratory Disease Study Group (ORDSG). Senoo S, et al. Among authors: hara n. PLoS One. 2020 Aug 27;15(8):e0236935. doi: 10.1371/journal.pone.0236935. eCollection 2020. PLoS One. 2020. PMID: 32853277 Free PMC article.
Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial.
Makimoto G, Hotta K, Oze I, Ninomiya K, Nakanishi M, Hara N, Kano H, Watanabe H, Hata Y, Nishii K, Nakasuka T, Itano J, Ninomiya T, Kubo T, Ohashi K, Ichihara E, Minami D, Sato A, Tabata M, Maeda Y, Kiura K. Makimoto G, et al. Among authors: hara n. Asia Pac J Clin Oncol. 2021 Feb;17(1):101-108. doi: 10.1111/ajco.13423. Epub 2020 Sep 3. Asia Pac J Clin Oncol. 2021. PMID: 32885583 Clinical Trial.
1,090 results